Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
11.92
-0.15 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 24, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 10, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
November 08, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
September 21, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
September 14, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
August 23, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 13, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 12, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
June 28, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
June 05, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 27, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
May 10, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
May 03, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
April 20, 2021
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.